Evidence map›Paper›PMID 39475963›Full record

ArticlePloS one2024

Exploring the photosensitizing potential of Nanoliposome Loaded Improved Toluidine Blue O (NLITBO) Against Streptococcus mutans: An in-vitro feasibility study.

Swagatika Panda, Lipsa Rout, Neeta Mohanty, Anurag Satpathy, Bhabani Sankar Satapathy, Shakti Rath, Divya Gopinath

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Membrane Vesicles ImproveMicroorganisms · 2026
    Article
  2. Review
  3. Review
  4. Recent Advances in Nanoparticle-Mediated Antibacterial Photodynamic Therapy.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Swagatika PandaDepartment of Oral Pathology and Microbiology, Institute of Dental Sciences, Siksha'O'Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.ORCID 0000-0002-7449-3974
Lipsa RoutInstitute of Dental Sciences, Siksha'O'Anusandhan Deemed to be University. Bhubaneswar, Odisha, India.
Neeta MohantyDepartment of Oral Pathology and Microbiology, Institute of Dental Sciences, Siksha'O'Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.
Anurag SatpathyDepartment of Periodontics and Implantology, Institute of Dental Sciences, Siksha'O'Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.
Bhabani Sankar SatapathyGitam School of Pharmacy, Gitam (Deemed to be) University, Hyderabad, Telangana, India.
Shakti RathDepartment of Microbiology & Research, Institute of Dental Sciences, Siksha'O'Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.ORCID 0000-0003-3249-9080
Divya GopinathBasic Medical and Dental Sciences Dept, College of Dentistry, Ajman University, Ajman, United Arab Emirates.ORCID 0000-0002-4279-7420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStreptococcus mutans is a major contributor to dental caries due to its ability to produce acid and survive in biofilms. Microbial resistance towards common antimicrobial agents like chlorhexidine and triclosan has shifted the research towards antimicrobial Photodynamic therapy (PDT). In this context, Toluidine Blue O (TBO) is being explored for its photosensitizing properties against Streptococcus mutans. There is a huge variation in the effective concentration of TBO among the current studies owing to the differences in source of and delivery system TBO as well as the time, power and energy densities of light.

objectiveThe primary objectives of this study are to encapsulate improved Toluidine Blue O (ITBO) in nanoliposomes (NLITBO), characterize it, and evaluate its antibacterial photosensitizing potential against Streptococcus mutans suspensions in vitro.

methodITBO was synthesised as per Indian patent (number -543908). NLITBO was prepared using the thin-film hydration method. Dynamic light scattering experiment determined the vesicle size, polydispersity index (PDI), and zeta potential. Surface features were characterized by Scanning and Transmission Electron microscopy. ITBO release from NLITBO was assessed using the extrapolation method. The antibacterial activity of the NLITBO was determined by evaluating the zone of inhibition (ZOI) in the Streptococcus mutans culture and comparing with 2% chlorhexidine gluconate. The minimum inhibitory concentration (MIC) of NLITBO as a photosensitizer with red light (wavelength 650nm, power density 0.1 W/cm2, energy density 9-9.1 J/ cm2, 90seconds time) was evaluated against Streptococcus mutans cells by colorimetric method in 96 well plate.

resultsPercentage drug loading, loading efficiency, yield percentage, vesicle size, PDI, Zeta potential of NLTBO was reported as 9.3±0.4%, 84.4±7.6%, 73.5%, 123.52 nm, 0.57, -39.54mV respectively. Clusters of uni-lamellar nanovesicles with smooth non-perforated surfaces were observed in SEM and TEM. The size of the vesicle was within 100 nm. At 24 hours, a cumulative 79.81% of ITBO was released from NLITBO. Mean ZOI and MIC of NLITBO (1 μg /ml) were found to be 0.7±0.2 mm, 0.6μg/ml respectively.

conclusionWe have synthesized and encapsulated improved Toluidine Blue O (ITBO) in nanoliposomes (NLITBO) and thoroughly characterized the formulation. The antibacterial efficacy of NLITBO without light was demonstrated by ZOI which is similar to 2% chlorhexidine gluconate. MIC of NLITBO as a photosensitiser along with the optimal light parameter was also proposed in this study. These findings suggested that NLITBO could serve as an effective alternative to conventional antibacterial treatments in managing Streptococcus mutans rich biofilms. It can have potential pharmaceutical application in oral health care.

Indexed as

LiposomesPhotosensitizing AgentsStreptococcus mutansTolonium ChlorideAnti-Bacterial AgentsBiofilmsFeasibility StudiesMicrobial Sensitivity TestsNanoparticlesPhotochemotherapyAnti-Bacterial AgentsLiposomesPhotosensitizing AgentsTolonium Chloride

Identifiers

PMID39475963
PMCPMC11524459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.